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Maternal HtrA3 optimizes placental 
development to influence offspring 
birth weight and subsequent white 
fat gain in adulthood
Ying Li1,2, Lois A. Salamonsen1,2,3, Jonathan Hyett4,5, Fabricio da Silva Costa3,6 &  
Guiying Nie1,2,7
High temperature requirement factor A3 (HtrA3), a member of the HtrA protease family, is highly 
expressed in the developing placenta, including the maternal decidual cells in both mice and humans. 
In this study we deleted the HtrA3 gene in the mouse and crossed females carrying zero, one, or 
two HtrA3-expressing alleles with HtrA3+/− males to investigate the role of maternal vs fetal HtrA3 
in placentation. Although HtrA3−/− mice were phenotypically normal and fertile, HtrA3 deletion in 
the mother resulted in intra-uterine growth restriction (IUGR). Disorganization of labyrinthine fetal 
capillaries was the major placental defect when HtrA3 was absent. The IUGR caused by maternal 
HtrA3 deletion, albeit being mild, significantly altered offspring growth trajectory long after birth. 
By 8 months of age, mice born to HtrA3-deficient mothers, independent of their own genotype, were 
significantly heavier and contained a larger mass of white fat. We further demonstrated that in women 
serum levels of HtrA3 during early pregnancy were significantly lower in IUGR pregnancies, establishing 
an association between lower HtrA3 levels and placental insufficiency in the human. This study thus 
revealed the importance of maternal HtrA3 in optimizing placental development and its long-term 
impact on the offspring well beyond in utero growth.
High-temperature requirement factor A (HtrA) proteins are a family of serine proteases with functional impor-
tance in regulating protein-protein interactions and protein folding stress1. To date, four mammalian HtrAs 
(HtrA1-4) have been identified1–7, and their dysregulation is associated with a number of diseases, including 
cancer, arthritis, neurodegenerative disorders, age-related macular degeneration, and pregnancy diseases8–17. In 
particular, HtrA1 and HtrA3 have been suggested as tumor suppressors, because they are down-regulated in a 
number of cancers and this reduction is suggested to promote tumorigenesis18–22. HtrA3 down-regulation in 
lung cancer is believed to occur because cigarette smoking induces methylation of the HtrA3 gene8. The reduced 
HtrA3 expression is further linked to diminished effectiveness of anti-cancer treatment of lung cancer23, and 
increased risk of postoperative recurrence of the tumor24.
HtrA3 was initially cloned, in both the mouse and human, from the developing placenta because of high 
HtrA3 expression5, 6, 25, 26. In both species, alternative splicing gives rises to two HtrA3 mRNA transcripts and 
two HtrA3 proteins isoforms, the long (HtrA3-L) and short (HtrA3-S) variants5, 6. HtrA3-L protein is comprised 
of five major domains, the signal peptide, IGF binding, Kazal inhibitor, trypsin-like serine protease and PDZ 
domains5, 6 (Supplementary Figure 1A). HtrA3-S lacks the C-terminal PDZ domain, but otherwise is identical 
to HtrA3-L5, 6 (Supplementary Figure 1A). HtrA3 gene structure and protein sequences are highly conserved 
between the mouse and human5, 6. While the mouse expresses the HtrA3-L isoform predominantly, both HtrA3 
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isoforms are produced comparably in the human5, 6. Both human HtrA3 isoforms are confirmed to be proteolyti-
cally active27. To date, it is unknown whether the two HtrA3 isoforms exert distinctive functions.
In the mouse, HtrA3 expression is markedly up-regulated in the uterus during placental development6. 
Specifically, the maternal decidual cells within the decidua basalis strongly express HtrA3, and the level is high-
est during early pregnancy when the placenta is actively developing26. In the human, HtrA3 is also abundantly 
expressed in the developing placenta, with the level being maximal during the first trimester of pregnancy25. 
Again, HtrA3 is highly expressed in maternal decidual cells during human placental development25. In women, 
HtrA3 is additionally expressed by a number of trophoblast subtypes including the villous syncytiotrophoblast, 
during the first trimester of pregnancy25. This placental HtrA3 is secreted into the maternal circulation with 
HtrA3 serum levels reflecting placental production, being highest in the first and lowest in the third trimester of 
pregnancy12.
In vitro studies indicate that HtrA3 negatively regulates trophoblast invasion during human placentation28, 29. 
Furthermore, serum levels of HtrA3 are altered during early pregnancy in women who subsequently develop 
preeclampsia in the third trimester12, 30. As defective placentation is a major cause of preeclampsia31, this data 
suggests an association between HtrA3 alteration and placental abnormalities. A recent study identified HtrA3 as 
a potential target of a prolactin family paralog in maternal decidual cells during mouse placental development32. 
However, to date, the functional importance of HtrA3 in placental development and function is unknown.
In the present study, we created an HtrA3 null mouse model and investigated the importance of HtrA3 in pla-
cental development. The HtrA3−/− mice were fertile and phenotypically normal. As the mouse and human both 
develop a hemochorial placenta, requiring highly regulated participation of both fetal and maternal cells33, 34, and 
HtrA3 is highly expressed in maternal decidual cells during placentation26, we investigated the consequence of 
deleting the maternal vs fetal HtrA3 on placentation and fetal growth. Strikingly, HtrA3 deletion in the mother 
but not in the fetus, resulted in placental insufficiency and intra-uterine fetal growth restriction (IUGR). This 
IUGR, caused by HtrA3 deficiency in the mother, altered the growth trajectory of the offspring, independent of 
their genotype. To establish that the mouse data are relevant to the human, we also investigated the association 
between maternal serum levels of HtrA3 during placental development and IUGR in human pregnancies.
Results
Targeted disruption of the HtrA3 gene in the mouse. The structure of the mouse HtrA3 gene 
(27760 bp, located on chromosome 5) is schematically illustrated in Supplementary Figure 1A. It contains 10 
exons; alternative splicing leads to two HtrA3 mRNA transcripts (L-mRNA and S-mRNA), which translate into 
two protein isoforms (L-Protein, 459; S-Protein, 363aa)5. Exons 1–6 are transcribed into both HtrA3 mRNA 
transcripts, whereas exons 8, 9 and 10 are specific to the long and exon 7 is unique to the short HtrA3 mRNA 
transcript5 (Supplementary Figure 1A). Although exons 10 and 7 are the largest exons of the HtrA3 L-mRNA and 
S-mRNA respectively, both predominantly code for the 3′ untranslated region (Supplementary Figure 1A). In 
contrast, exon 1 is the largest coding exon of both HtrA3 L-mRNA and S-mRNA, containing the ATG translation 
start codon and coding for three protein domains (signal peptide, IGF binding and Kazal inhibitor domains) 
which are common to both HtrA3 protein isoforms (L-Protein and S-Protein)5 (Supplementary Figure 1A).
To remove both HtrA3 protein isoforms, we deleted the entire exon 1 and its flanking sequences with the tar-
geting strategy shown in Supplementary Figure 1B. This deletion, further detailed in Supplementary Figure 1C, 
was predicted to prevent all HtrA3 transcription because an 880 bp regulatory sequence that precedes exon 1 was 
also removed.
Southern blot analysis confirmed the correct targeting of ES cells and germline transmission of the deletion 
(Fig. 1A). Genomic DNA from ES cells and heterozygous mice born from chimeras was digested with SapI and 
probed with the 3′ probe illustrated in Supplementary Figure 1B. The wild type mouse showed a 14.1 kb band 
corresponding to the wild type allele, whereas the targeted ES cells and HtrA3+/− mice showed an additional band 
of 12.6 kb consistent with the null allele (Fig. 1A, Southern blot).
Intercrossing these HtrA3+/− mice produced three genotypes of mice, including HtrA3−/− homozygotes. Tail 
DNA from these mice was analyzed by PCR (Fig. 1A), using the scheme and primers illustrated in Supplementary 
Figure 1C. The band pattern and sizes of each genotype were exactly as expected (Fig. 1A and Supplementary 1C), 
validating the PCR strategy for genotyping.
Northern blot analysis confirmed a clear reduction in the HtrA3−/− heterozygotes, and a total deletion in the 
HtrA3−/− homozygotes, of both HtrA3 mRNA transcripts. Figure 1B shows the analysis of day (d)10.5 implan-
tation sites, the tissue expressing high levels of HtrA3 in mice26. Four distinct probes, schematically shown in 
Supplementary Figure 1A, were employed to detect different parts of the HtrA3 mRNA: the deleted region (probe 
1), sequence that is downstream of the deleted region but common to both HtrA3 mRNA transcripts (probe 2), 
and sequences specific to HtrA3 L-mRNA (probe 3) and S-mRNA (probe 4) variants. All four probes showed that 
the HtrA3 mRNA was reduced in HtrA3+/− and absent in HtrA3−/− mice (Fig. 1B).
Deletion of both HtrA3 protein isoforms was further confirmed by Western blot analysis of d10.5 implanta-
tion sites (Fig. 1C), using an antibody detecting both HtrA3 isoforms. No bands of HtrA3 protein were detected 
in the HtrA3−/− mice. Immunohistochemistry further corroborated this total deletion. In the wild type mice, 
HtrA3 protein was immuno-stained predominantly in the decidua basalis of d10.5 implantation sites (Fig. 1C), 
consistent with previous findings26. However, this staining was totally absent in the HtrA3−/− mice (Fig. 1C). 
These analyses confirmed total deletion of HtrA3 expression in the HtrA3−/− mice.
Breeding analysis. The HtrA3−/− mice appeared normal, showing no obvious phenotypic abnormalities. 
To assess whether the HtrA3 deletion affects fertility, we set up all 9 possible crossings by mating females of three 
HtrA3 genotypes (+/+, +/− and −/−) with males of three HtrA3 genotypes (Table 1). All crossings produced 
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viable pups in the expected Mendelian ratio, with no differences in litter size at birth or weaning (Table 1), indi-
cating that HtrA3 deletion was not detrimental to female or male fertility.
As mouse HtrA3 is highly expressed in maternal decidual cells during placental development26, we next 
assessed whether HtrA3 deletion affects placental development and thus fetal growth. The mouse placenta is com-
prised of two major components, the maternal decidua basalis (DB) and the fetal placenta (F Pla) (Fig. 2A, top 
right corner)26, 34. The fetal placenta here refers to the labyrinth and the junctional zone. All these components are 
important for the development of an optimal placenta. During placentation, the maternal decidua regresses pro-
gressively whereas the fetal placenta enlarges dramatically26, 35, 36. Genetically, the maternal decidua is identical to 
the mother, whereas the fetal placenta is similar to the fetus. Therefore the fetal as well as the maternal genotype, 
which can be different from each other, jointly determine the placental genotype. As HtrA3 is expressed predom-
inantly in the maternal decidua basalis (Fig. 1C)26, we employed the breeding strategy shown in Fig. 2A to deter-
mine the contribution of the maternal and fetal HtrA3 to placental development and fetal growth. Females of all 
Figure 1. Confirmation of HtrA3 gene deletion in the mouse. (A) Southern blot analysis. Tail DNA from the 
wild type (+/+) and first generation heterozygous (+/−) mice, and genomic DNA from targeted ES cells, 
were digested with Sap1 and analyzed with the 3′ probe shown in Supplementary Fig. 1B. The band size of 
the wild type (14.1 kb) and the null (12.6 kb) alleles are shown. PCR analysis. Tail DNA from 3 representative 
HtrA3 genotypes of mice were analyzed by PCR using the 3 genotyping primers (F, R1 and R2) illustrated in 
Supplementary Fig.1C; the resulting products (374 and 271 bp) and band pattern were precisely as predicted. 
(B) Northern blot analysis. Total RNA from d10.5 implantation sites were analyzed by the 4 distinct probes 
shown in Supplementary Fig. 1(A). Probe 1, specific to exon 1 (deleted); probe 2, downstream of the deleted 
region and common to both HtrA3 mRNAs; probe 3, specific to HtrA3 L-mRNA (~2.8 kb); probe 4, unique to 
HtrA3 S-mRNA (~2.2 kb). Detection with probe 4 required a much longer exposure because of much lower 
expression of the HtrA3 S-mRNA. (C) Western blot analysis. Total protein lysates from d10.5 implantation sites 
were examined on two identical gels. Left panel, Western blot analysis; right panel, Coomassie blue staining 
showing equal loading. Immunohistochemistry. D10.5 implantation sites were analyzed, HtrA3 was immuno-
stained (brown) predominantly in maternal decidua basalis of +/+ but not −/− mice; the inserts are negatives. 
MT, maternal uterine metrial triangle. An antibody detecting both HtrA3 protein isoforms were used for the 
protein analysis.
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three genotypes (HtrA3+/+,+/− and −/−) were crossed with heterozygous (HtrA3+/−) males to generate 3 possible 
genotypes of fetuses (HtrA3+/+,+/− and −/−) and 7 possible genotypes of placentas (Fig. 2A). The HtrA3 genotype 
of the maternal decidua basalis and the fetal placenta of each placental type is schematically illustrated in Fig. 2A.
These crossings produced viable fetuses in the expected Mendelian ratio (data not shown). There was no dif-
ference in embryonic day (E) 18 fetal weight when analyzed according to the fetal genotype (Fig. 2B). However, 
when analyzed according to the maternal genotype, E18 fetal weights differed: fetuses of HtrA3+/− or HtrA3−/− 
mothers were significantly lighter than those of HtrA3+/+ mothers (Fig. 2C), suggesting that HtrA3 deletion in 
the mother affected the fetal growth in utero. We next analyzed E18 fetal weight according to the genotype of the 
mother as well as the fetus, which separated them into 7 groups (Fig. 2D). The maternal genotype of HtrA3+/+ 
fetuses (Fig. 2D, left), could be HtrA3+/+ (Fig. 2D-a) or HtrA3+/− (Fig. 2D-b). The mothers of HtrA3+/− fetuses 
(Fig. 2D, middle), could be HtrA3+/+ (Fig. 2D-c), HtrA3+/− (Fig. 2D-d) or HtrA3−/− (Fig. 2D-e). The HtrA3−/− 
fetuses (Fig. 2D, right), could come from HtrA3+/− (Fig. 2D-f) or HtrA3−/− (Fig. 2D-g) mothers. These 7 groups 
of fetuses were supported in utero by the 7 distinctive placentas respectively (Fig. 2D and A).
Within each fetal genotype, deletion of maternal HtrA3 reduced E18 weight (Fig. 2D). For the HtrA3+/+ 
fetuses (Fig. 2D, left), although all genetically similar (wild type), those from HtrA3+/− mothers (Fig. 2D-b) had 
significantly lower E18 weight than fetuses from HtrA3+/+ mothers (Fig. 2D-a). For the HtrA3+/− fetuses (Fig. 2D, 
middle), again all genetically similar, E18 weight was highest if the mother was HtrA3+/+ (Fig. 2D-c) and lowest 
if the mother was HtrA3−/− (Fig. 2D-e); fetuses of HtrA3+/− mothers (Fig. 2D-d) bridged the two extremes: their 
E18 weight was significantly lower than those of HtrA3+/+ mothers. A similar trend was apparent but not signifi-
cant for the HtrA3−/− fetuses (Fig. 2D, f-g). Since all differences were consistent between male and female fetuses: 
combined data is presented.
Placental analysis. As fetal growth in utero depends on placental function, we analyzed the 7 genotypes 
of placentas that supported the above 7 groups of fetuses. The intact implantation sites containing the mater-
nal decidua basalis and the fetal placenta were investigated at three developmental stages, d10.5, when the fetal 
placenta has just formed but is thin relative to the maternal decidua basalis; d13, when the fetal placenta has 
fully formed and the maternal decidua basalis is still present; and d16, when the fetal placenta has substantially 
expanded and the maternal decidua basalis has considerably regressed26.
H&E staining revealed no obvious differences in gross morphology among these placentas. Specific markers 
were thus employed to closely examine the decidua basalis and the fetal placenta respectively. The decidua basalis 
was analyzed by immuno-staining the stromal decidual cells for marker desmin26, and by lectin-DBA staining for 
uNK cells that constitute the most abundant immune cells in the decidua during placentation26, 37. The desmin 
staining pattern and NK cell presentation were similar among these placentas at all three developmental stages 
(data not shown). The decidual endothelium was examined by immuno-staining for Factor VIII38, and spiral 
arterial remodelling was analyzed by immno-staining for smooth muscle actin38. These analyses likewise revealed 
no clear differences, indicating that HtrA3 deletion did not affect the morphology of the maternal decidua basalis.
We also examined the junctional zone and the labyrinth of the fetal placenta. The gross architecture of these 
components was not different among these placentas. The glycogen cells, the major cell type of the junctional 
zone, were identified by staining with periodic acid–schiff (PAS) with and without digestion with α-amylase38, 
and immuno-staining for CX3139, but no major differences were apparent. Glycogen cells that have invaded into 
the maternal decidua basalis, immuno-stained for decorin39, also appeared to be similar (data not shown). These 
results thus suggest that HtrA3 deletion does not affect the glycogen cells within the junctional zone or their 
invasion into the maternal decidua.
The labyrinth is primarily responsible for nutrient and gas exchange between the mother and fetus. We closely 
examined the two major labyrinthine components, the maternal blood sinuses and fetal capillaries. The maternal 
blood sinuses, identified by staining the trophoblasts lining these spaces for alkaline phosphatase activity40, or for 
isolectin BS1 binding41, showed no clear differences.
However, the fetal capillary endothelium, detected by immuno-staining for laminin40, was distinct from d13 
and the differences were profound at d16 (Fig. 3). A small schematic drawing at the bottom right corner of 
each fetal capillary image in Fig. 3 denotes the HtrA3 genotype of that specific placenta, the genotype of the 
maternal decidua basalis is shown in blue and that of the fetal placenta in red. The wild type placentas (+/+/+/+, 
Mating (F × M) n
Litter size at
Birth Weaning
+/+ × +/+ 7 6.9 ± 0.6 6.6 ± 0.7
+/+ ×  +/− 7 7.1 ± 0.6 6.7 ± 0.5
+/+ × −/− 6 6.2 ± 1.1 5.7 ± 0.8
+/− × +/+ 3 6.0 ± 1.5 5.7 ± 1.5
+/− × +/− 7 7.7 ± 0.3 7.4 ± 0.2
+/− × −/− 6 6.5 ± 0.8 6.3 ± 0.9
−/− × +/+ 3 7.3 ± 1.5 7.3 ± 1.5
−/− × +/− 6 6.0 ± 0.9 5.7 ± 1.0
−/− × −/− 8 7.4 ± 0.8 7.0 ± 0.8
Table 1. Breeding results from 9 different types of mating.
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Figure 2. The impact of HtrA3 gene deletion in the mother versus fetus on E18 fetal weight. (A) The mating 
scheme to analyze the maternal and fetal contribution to the genomic makeup of the placenta. The top row 
illustrates that when a female (♀) is mated to a male (♂) mouse, the resulting fetus and placenta will be 
genetically related but not identical. The mouse placenta is comprised of maternal decidua basalis (DB) and 
fetal placenta (F Pla), genetically the maternal component will be identical to the mother, whereas the fetal 
component will be similar to the fetus. An actual image of a d10.5 placental section is shown at the far right 
top corner, displaying the maternal DB on the top (stained for desmin in brown) and the F Pla on the bottom. 
Immediately below it is a schematic drawing of the placenta, showing the maternal DB on the top in blue and 
F Pla on the bottom in red. The lower section of the figure shows the scheme for mating female mice of three 
HtrA3 genotypes (+/+, +/− or −/−) with males of HtrA3 heterozygous (+/−) to generate three HtrA3 
genotypes (+/+, +/− or −/−) of fetuses but seven genotypes of placentas. Each placental type is schematically 
drawn to show the HtrA3 genotype of the maternal DB (top in blue) and the F Pla (bottom in red). (B–D) Fetal 
weight at E18. Data were analyzed according to the genotype of the fetus (B), the mother (C), and the fetus as 
well as the mother (D). The number of fetuses examined for each group is shown on the graph. The 7 distinctive 
groups in (D) are labeled as “a, b, c, d, e, f, g” respectively, and this labelling system is consistently applied to 
other figures. Data are expressed as mean ± SD. *p < 0.05.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 4627  | DOI:10.1038/s41598-017-04867-3
Fig. 3A-a), without any HtrA3 deletion in either the maternal decidua basalis or the fetal placenta, displayed a 
well-structured and regularly-spaced fetal capillary network. However, this structure was altered when one HtrA3 
allele was deleted only in the maternal decidua basalis and not in the fetal placenta (+/−/+/+, Fig. 3A-b), the capil-
laries were not as well organized/connected (Fig. 3A-b vs A-a). This alteration was reflected by a significant reduc-
tion in laminin staining intensity (Fig. 3B-b vs B-a). This data indicates that maternal HtrA3 promotes optimal 
development of the labyrinth fetal capillaries. This is consistent with the wild type E18 fetuses of HtrA3+/− moth-
ers (Fig. 2D-b, supported by +/−/+/+ placentas) having lower weight than those of HtrA3+/+ mothers (Fig. 2D-a, 
supported by +/+/+/+ placentas).
When one HtrA3 allele was deleted in the fetal placenta but the maternal decidua basalis was wild type 
(+/+/+/−, Fig. 3A-c), the fetal capillary appearance was also altered compared to the wild type (+/+/+/+, Fig. 3A-a), 
but the disturbance was less severe. This may explain the lack of difference in E18 weight between HtrA3+/− and 
HtrA3+/+ fetuses from wild type mothers (with +/+/+/− and +/+/+/+ placentas respectively, Fig. 2D-c and D-a).
Figure 3. Analysis of fetal capillaries within the placental labyrinth at d16.5. (A) Representative images of 
immuno-staining for laminin to identify fetal capillaries. All 7 possible placental types illustrated in Fig. 2A are 
presented. The HtrA3 genotype of each placental type is schematically shown at the bottom right corner of each 
image, denoting the maternal decidua basalis genotype in blue on the top and the fetal placental genotype in red 
on the bottom. The labelling of individual type (a-g) is consistent with the labelling of Fig. 2D. (B) Quantitative 
analysis of laminin staining of the 7 distinctive placentas. Each type (a-g) is labelled consistently between (A) 
and (B). Data are expressed as mean ± SD. *p < 0.05, **p < 0.01.
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The fetal placentas of Fig. 3A-c,d and e were all HtrA3+/−, but their maternal decidua basalis was respectively 
HtrA3+/+ (Fig. 3A-c), HtrA3+/− (Fig. 3A-d), and HtrA3−/− (Fig. 3A-e). The fetal capillary networks of 3A-d and 
3A-e were more disorganized than that of 3A-c, and their laminin staining intensity was likewise significantly 
reduced (Fig. 3B-d and B-e vs B-c). This provides further evidence that maternal HtrA3 is important for optimal 
development of fetal capillaries in the labyrinth. This is consistent with the weight of HtrA3+/− fetuses at E18 
being highest when the mother was HtrA3+/+ (Fig. 2D-c) and reduced when the mother was HtrA3+/− or −/− 
(Fig. 2D-d and D-e).
All placentas with one or both HtrA3 alleles deleted in both maternal and fetal compartments (Fig. 3A-f and 
A-g), showed abnormal fetal capillaries compared with wild type (Fig. 3A-a), suggesting that the maternal decid-
ual and fetal placental HtrA3 may synergistically influence the labyrinthine fetal capillary development. However, 
the placenta still developed even when HtrA3 was totally deleted in both components (Fig. 3A-g), suggesting an 
important supportive rather than a pivotal role of HtrA3 in mouse placentation. These data are in agreement 
with HtrA3−/− fetuses being viable but with reduced E18 weight when their mothers were HtrA3+/− or HtrA3−/− 
(Fig. 2D-f and D-g).
Postnatal growth. As IUGR can have long lasting impact on postnatal health, we examined whether the 
observed mild fetal growth restriction, resulting from suboptimal placentation due to HtrA3 deletion in the 
mother, would affect the offspring postnatally. Following the breeding scheme of Fig. 2A with extension to natural 
birth, the postnatal growth of the pups was monitored. Because body weight differs significantly between sexes, 
females and males were analyzed separately (Figs 4 and 5 respectively). The offspring were again separated into 7 
groups according to their own HtrA3 genotype as well as that of their mothers (Figs 4 and 5).
For all female offspring (Fig. 4), body weight was similar at 1 month of age (Fig. 4A,B), but clearly differed over 
time and at 8 months (mid-adulthood) (Fig. 4A and C). Overall at 8 months of age (Fig. 4C), offspring born to 
HtrA3−/− mothers were heavier than those of HtrA3+/+ mothers, the reverse of their relative fetal weights at E18 
(Fig. 2D). Those born to HtrA3+/− mothers showed a non-significant trend to increased weight. There was no 
difference in weights of wild-type offspring with wild-type or heterozygous mothers. These differences in body 
weight were likewise observed in male offspring at 8 months of age (Fig. 5A–C).
To further explore this increase in offspring body weight, we analyzed the weight of 10 major organs at 8 
months of age. Among gonadal fat pads, visceral fat, brown fat, liver, heart, kidney, spleen, pancreas, quadriceps 
muscle, and bone (right upper leg), only gonadal fat differed significantly (Figs 4D and 5D). Within each geno-
type, the gonadal fat was heavier in offspring of HtrA3+/− or HtrA3−/− mothers than wild-type mothers (Figs 4D 
and 5D), mirroring the pattern of their body weight (Figs 4C and 5C). The weights of other organs examined, 
including quadriceps muscle (Figs 4E and 5E), were not significantly different. These data thus suggest that the 
gonadal fat, the largest storage of white fat in the body, is a major contributor to the body weight increase. These 
results also established an inverse relationship between fetal weight at E18 in utero (Fig. 2D), and body and 
gonadal fat weight in adulthood (Figs 4C,D and 5C,D). Since these comparisons were between mice of similar 
genotype but with different maternal genotype, it is clear that maternal HtrA3, acting via promotion of optimal 
placental development, has long-lasting impact on the offspring.
Serum HtrA3 levels in women during early gestation were lower in IUGR pregnancies. In the 
human, HtrA3 is highly expressed in the maternal decidual cells and various types of trophoblasts during placen-
tal development25. In addition, in the human but not in the mouse, HtrA3 is secreted into the maternal circula-
tion25. HtrA3 serum concentrations, reflecting decidual and placental production, are highest in the first trimester 
when the placenta is developing25. We thus investigated whether serum HtrA3 concentrations in women during 
early gestation are different between normal and IUGR pregnancies. We examined a cohort of sera collected at 
11–13 weeks of gestation from 363 singleton pregnancies. These women gave birth to normal weight (control, 
n = 292) or IUGR (<5th percentile, n = 71) babies. Serum HtrA3 levels were significantly lower (p < 0.05) in 
IUGR than control pregnancies (Fig. 6).
Discussion
In this study, we investigated the importance of HtrA3 in mouse placentation using a gene deletion strategy. 
Because a hemochorial placenta requires both fetal and maternal components, and HtrA3 is restricted to the 
maternal decidual cells in mice, we examined the contribution of maternal vs fetal HtrA3 to placental develop-
ment. Using a simple but effective mating scheme, a significant supportive role of maternally-derived HtrA3 in 
optimizing placental development and fetal growth was revealed. The data clearly showed that HtrA3 deletion 
in the mother affected the organization of the labyrinthine fetal capillaries, which are directly responsible for 
fetal-maternal exchange. Consistent with this abnormality, deletion of maternal HtrA3 compromised placental 
function and caused fetal growth restriction irrespective of fetal genotype. Although mild, the IUGR caused by 
HtrA3 deficiency in the mother significantly affected the growth trajectory of the offspring independent of their 
own genotype. By adulthood of 8 months of age, mice of identical genotype differed significantly in body weight 
and white adipose fat content, because of their mothers’ HtrA3 genotype; those born to HtrA3-deficient mothers 
were significantly heavier with more white fat. Furthermore, in pregnant women, serum levels of HtrA3 during 
early pregnancy were significantly lower in those who subsequently developed IUGR, establishing an association 
between lower HtrA3 levels early in pregnancy and placental insufficiency in the human. Collectively these stud-
ies demonstrate the importance of HtrA3 in optimizing placental development in mice and humans.
HtrA3 does not appear to be essential for fetal development, as HtrA3−/− mice were born in the expected 
Mendelian distribution and phenotypically normal. This is also the case for HtrA1 and HtrA4 when they are 
deleted from the mouse genome42–44. However, our results clearly identify that maternal HtrA3 is critical for 
the development of an optimal and efficient placenta. The major placental defect associated with HtrA3 
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deletion was disorganization of labyrinthine fetal capillaries. Not surprisingly, this defect resulted in fetal growth 
restriction because the labyrinthine vasculature is vital to placental function. In mice, the labyrinth comprises 
finely-branched and interdigitated maternal and fetal blood spaces, which facilitate transfer of nutrients from 
Figure 4. The impact of HtrA3 gene deletion in the mother versus fetus on postnatal body weight and organ 
weight in the female offspring. Female mice of three HtrA3 genotypes were crossed with HtrA3+/− males as 
shown in Fig. 2A, and the resulting mice were monitored postnatally. The data from female offspring were 
analyzed according to their genotype as well as the genotype of their mothers, and are presented in the same 
format as Fig. 2D. (A) Body weight change over the period of 34 weeks. (B,C) Comparison of body weight 
across all 7 groups at one (B) and eight (C) months of age respectively. (D,E) Weight of gonadal fat (D) and 
quadriceps muscle (E) at eight months of age. The numbers of mice examined for each group (similar across A–
E): a, n = 19; b, n = 9; c, n = 11; d, n = 13; e, n = 11; f, n = 9; g, n = 8. The labelling of a-g is shown on the graph of 
(C) only. Data are expressed as mean ± SD. *p < 0.05.
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the mother to the fetus38, 45. Consequently, severe abnormalities in this region lead to fetal death, while mild 
defects cause fetal growth restriction45–47. For instance, deletion of HOXA13, PPARγ, HAI-1 or the retinoblas-
toma gene in mice all results in embryonic lethality because of severe labyrinthine defects41, 48–50, whereas lack of 
placenta-specific IGF-II or p45NF-E2 leads to placental insufficiency and fetal growth restriction51, 52.
As all blood spaces within the labyrinth are lined by fetal-derived trophoblasts, the majority of labyrinthine 
defects reported to date are caused by ablation of genes expressed in these cells41, 45–52. In contrast, only a few 
Figure 5. The impact of HtrA3 gene deletion in the mother versus fetus on postnatal body weight and organ 
weight in the male offspring. Male mice born from the Fig. 2A mating scheme were analyzed according to the 
genotype of the offspring as well as the genotype of their mothers, and the data are presented in the same format 
as Fig. 4. (A) Body weight change over the period of 34 weeks. (C,D) Comparison of body weight at one (B) and 
eight (C) months of age respectively. (D,E) Weight of gonadal fat (D) and quadriceps muscle (E) at eight months 
of age. The numbers of mice examined for each group (similar across A–E): a, n = 11; b, n = 13; c, n = 12; d, 
n = 11; e, n = 11; f, n = 11; g, n = 9. The labelling of a-g is shown on the graph of (C) only. Data are expressed as 
mean ± SD. *p < 0.05.
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studies have reported labyrinthine abnormalities following alteration of maternally derived factors. Partial 
maternal deficiency of maternal Hmox1 is reported to reduce labyrinthine vasculature volume irrespective of 
fetal genotype53. Overexpression of maternal IGFBP-1 results in enlargement of the labyrinth and IUGR, again 
independent of fetal genotype54. Our studies here provide further evidence that maternally-derived factors can 
influence labyrinthine formation and function. Future studies will investigate how maternal HtrA3 regulates 
labyrinthine development, including identifying HtrA3 substrates and whether the trophoblasts lining the laby-
rinthine fetal capillaries express very low levels of HtrA3 that is below the detection limit of the previously used 
methods of immunohistochemistry and in situ hybridization26, 42.
Deletion of HtrA1 in mice also results in poor placental development and IUGR42. However, the placental 
defects reported for HtrA1-deficient mice are more severe than in the HtrA3 null mice presented here. The pla-
centas of HtrA1−/− mice are smaller, their junctional zone is reduced and labyrinth vascularization impaired42. 
This is consistent with HtrA1 being expressed in the decidua capsularis in addition to trophoblast precursors36, 42, 
whereas HtrA3 is restricted to maternal decidual cells26, 42. In contrast, HtrA4 knockout mice are reported as 
phenotypically normal and fertile43; whether HtrA4 deletion causes subtle placental defects was not reported.
As HtrA3 is highly expressed in maternal decidual cells in both the mouse and human, it was speculated 
that HtrA3 may be required for the process of stromal decidualization25, 26. In this study, decidualization was 
unaffected in mice deficient in maternal HtrA3, providing strong evidence that HtrA3 is not essential for decid-
ualization at least in mice. However, trophoblast invasion differs considerably between the mouse and human. In 
mice, endovascular trophoblast invasion is shallow and interstitial trophoblast invasion occurs late in gestation, 
whereas in the human both endovascular and interstitial invasion is extensive and occurs early during preg-
nancy33, 34, 38. Therefore the role of decidual HtrA3 in human trophoblast invasion needs to be examined in the 
context of human placentation. In addition, as HtrA3 is expressed in specific trophoblast subtypes such as villous 
syncytiotrophoblast in the human but not in the mouse, the current mouse study does not shed light on the role 
of HtrA3 in trophoblast function. However, this study revealed that the maternal HtrA3 serum levels during early 
pregnancy were significantly lower in women with IUGR than normal pregnancies, implying that HtrA3 may 
also play an important role in optimizing placental development in the human. Future studies are warranted to 
establish the causal role of lower HtrA3 in human placental insufficiency. Although preeclampsia (especially the 
early-onset subtype) and IUGR are often (but not always) linked, HtrA3 serum levels at the end of first trimester 
are lower in IUGR (this study), but higher in women destined to develop preeclampsia12. These differences sug-
gest that HtrA3 is distinctively associated with IUGR and preeclamptic pregnancies.
This study further demonstrated the critical importance of the uterine environment on fetal growth and 
long-term consequences, consistent with the concept of developmental origins of health and disease (DOHaD)55–58. 
Epidemiological human studies have established that low birth weight is associated with increased rates of adi-
posity, type 2 diabetes, the metabolic syndrome, and other diseases in adult life56–59. This link has also been 
extensively investigated using animal models57, 60, 61. However, most animal studies induce significant fetal growth 
restrictions through severe maternal undernutrition, maternal uterine artery ligation, maternal ion deficiency, 
or a low protein diet, which are more appropriate to investigate famine conditions57, 62. While these approaches 
induce placental insufficiency, they are complicated by severe fetal nutrient restriction and significant fetal repro-
gramming57. The present work presents a unique model to investigate the relationship between subtle placental 
insufficiency, mild IUGR and long-term health consequences, which is more applicable to study the DOHaD 
phenomenon in the general population.
Figure 6. Serum HtrA3 concentration at 11-13 weeks of pregnancy in women who gave birth to normal 
(Control) or intra-uterine growth restricted (IUGR) babies. An ELISA detecting both HtrA3 isoforms was used 
to determine serum HtrA3 concentration. Data are presented in Tukey style box and whisker plots. Control, 
n = 292 (female, 134; male, 158); IUGR, n = 71 (female, 38; male, 33). p = 0.037. Median HtrA3 concentration 
was significantly lower in IUGR than control pregnancies.
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In addition, our studies present a scenario where adulthood overweight arises from subtle growth restriction 
in utero in the absence of maternal malnutrition or maternal endocrine disturbances. Importantly, such adverse 
outcomes are independent of an individual’s genetic composition, environmental insults or food access. These 
results strongly support the theory of the in utero origins of obesity57, and have important implications in the 
understanding of the current obesity epidemic.
In summary, the present study revealed the functional importance of HtrA3 in placental development. An 
effective mating strategy, rather than conditional knockout, was successfully utilized to investigate the contri-
bution of maternal vs fetal HtrA3 to placental development and function. Although HtrA3−/− mice appeared 
phenotypically normal with undisturbed reproductive function, the maternal HtrA3 played an important role 
in optimizing placental development and fetal growth. While loss of HtrA3 mildly affected fetal growth in utero, 
it significantly impacted the offspring’s growth trajectory well into adulthood. The association between lower 
maternal serum levels of HtrA3 early in gestation and IUGR pregnancies in women, suggests that HtrA3 may also 
play an important role in optimizing human placentation.
Methods
Targeted disruption of the HtrA3 gene in mice. A targeting construct (Supplementary Figure 1B), 
containing two loxP sites, a middle arm (MA) and a flippase recognition target (FRT)-neomycin cassette, was 
engineered using two BAC (bacterial artificial chromosome) clones spanning the required genomic region of the 
mouse HtrA3 gene and the ET cloning method63, 64. The construct was electroporated into embryonic stem (ES) 
cells derived from C57BL/6 mice. Exon 1 and the associated sequence were replaced through recombination by 
the middle arm, the neo cassette and the flanking loxP/FRT sites to produce the targeted allele (Supplementary 
Figure 1B). The ES cells were subsequently transfected with cre recombinase to remove the middle arm and the 
neo cassette to create the null allele (Supplementary Figure 1B). Genomic DNA of ES cells was digested with DrdI 
and SapI separately, and analyzed by standard Southern blot with the 5′ and 3′ probes shown in Supplementary 
Figure 1B. Correctly targeted ES cells were micro-injected into C57BL/6 J blastocysts and transferred into the 
uterus of recipient mice, the resulting chimeras were then crossed with C57BL/6 J mice to produce heterozygous 
offspring, and their tail DNA was analyzed by Southern blot as for the ES cells.
All mice were maintained on a C57BL/6 J background, and they were housed and handled according to the 
Monash University animal ethics guidelines. All studies were approved by the Animal Ethics Committee at the 
Monash Medical Centre, Melbourne, Australia.
Genotyping. Routine genotyping used a PCR strategy shown in Supplementary Figure 1C, with pro-
teinase K digested tail DNA and 55 °C annealing temperature. The primers used were: Forward (F), 
5′ACTCTGCTTCCTGGCTACTG3′ ; Reverse (R) 1, 5′GGAGGTCAAGTTGCTAGTGG3′ ; and R2, 
5′GCCCACCAGACGCTAC3′. PCR products from the very first analysis were confirmed by sequencing. The 
predicted PCR products of different genotypes are shown in the Table of Supplementary Figure 1C.
Confirmation of HtrA3 deletion at the mRNA and protein levels. Deletion of HtrA3 mRNA was 
confirmed by Northern blot analysis of total RNA from d10.5 implantation sites that contained the maternal 
decidua basalis as well as the fetal placenta as previously published26. The morning of finding a vaginal plug was 
designated as day 0 of pregnancy. Northern analysis utilized four distinct probes as illustrated in Supplementary 
Figure 1A, to detect different regions of the two HtrA3 mRNA variants. Each blot was also probed with a mouse 
cDNA for 18 S ribosomal RNA. HtrA3 proteins was confirmed by standard Western blot analysis of total proteins 
of d10.5 implantation sites as previously reported26. HtrA3 deletion was also confirmed by immunohistochemis-
try as published26. An HtrA3 antibody that was previously confirmed to detect both HtrA3 isoforms26, was used 
for both Western blot and immunohistochemical analyses.
Mouse breeding and analysis. To determine if HtrA3 deletion is detrimental to reproduction, female 
mice of three HtrA3 genotypes (+/+, +/− and −/−) were mated with the same three genotypes of male mice, 
and the resulting pups were counted and examined for gross abnormalities at birth and at weaning (4 weeks of 
age). To determine the contribution of maternal vs fetal HtrA3 to placental development and E18 fetal weight, the 
breeding strategy illustrated in Fig. 2A was utilized. Fetal sex at E18 was determined by PCR of Y chromosome 
specific gene SRY as previously reported65. The same breeding scheme was utilized to analyze the impact of HtrA3 
deletion in the mother vs fetus on offspring’s postnatal growth. The pups were born naturally, and their body 
weight was monitored monthly from weaning till 34 weeks (~8 months) of age. At the end of the experiment, 10 
major organs (gonadal fat pads, visceral fat, brown fat, liver, heart, kidney, spleen, pancreas, quadriceps muscle, 
and bone from the right upper leg) were carefully dissected and immediately weighed.
Histological analysis. Intact implantation sites containing the uterine, placental and fetal tissues were 
fixed in 10% neutral buffered formalin (pH 7.6) and processed as previously described26. All analyses employed 
5-micron sections, and all comparisons were made using mid-sagittal sections. All immuno-staining, except for 
Factor VIII, required antigen retrieval by microwaving the sections in 0.01 M citrate buffer for 10 min, and all 
were counter-stained with Harris’ hematoxylin (1:10) and mounted with DPX (BDH Chemicals, Kilsyth, Victoria, 
Australia).
The maternal decidual cells were immuno-stained for desmin26, the decidual NK cells were stained with 
lectin-DBA26, 37. The decidual endothelium was immuno-stained for Factor VIII38. The glycogen cells within the 
junctional zone were stained with periodic acid–schiff (PAS), followed by digestion without and with α-amylase 
as reported38. Junctional zone glycogen cells were also immuno-stained for CX3139. Glycogen cells in the maternal 
decidua were immuno-stained for decorin39. The alkaline phosphatase activity in the labyrinth was determined 
to analyze the maternal blood sinuses40. Maternal blood sinuses were also analyzed by isolectin BS1 binding as 
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published41. The fetal capillaries in the labyrinth were detected by immuno-staining for laminin40, using a rabbit 
anti-mouse laminin polyclonal antibody (Sigma Aldrich) and biotinylated goat anti-rabbit IgG (Vector labora-
tories) as the secondary antibody. To quantify laminin staining, images at 60x magnification were taken from 5 
different areas within each section, and the images were analysed by the Fiji open-source platform66. A total of 15 
areas from 3 different placentas were analysed for each unique placental type.
Analysis of HtrA3 in sera from pregnant women. An ELISA proven to detect both isoforms of HtrA3 
in human serum was employed to determine HtrA3 concentrations during early pregnancy. The cohort was 
collected at 11–13 weeks of pregnancy at Royal Prince Alfred Hospital, Sydney, Australia; the participants were 
originally recruited to a study evaluating an algorithm for predicting pregnancy diseases in the first trimester67, 68. 
For the current study, singleton pregnant sera from pregnancies that gave birth to normal weight (control) and 
IUGR (<5th percentile) babies were randomly selected from the above collection. Control, n = 292 (female, 134; 
male, 158). IUGR, n = 71 (female, 38; male, 33). The study was conducted in accordance with ethics approval 
from Royal Prince Alfred Hospital, Sydney, Australia (Study No. X11–0305 & HREC/11/RPAH/472).
Statistics. All statistical analysis used PRISM version 6.00 (GraphPad Software, San Diego, CA), and two-tail 
p < 0.05 was taken as significant. For the mouse studies, unpaired t-test (for 2 groups) or one-way ANOVA (3 
groups) were performed, and data expressed as mean ± SD. For the human studies, as the data was not normally 
distributed, Mann-Whitney analysis was used and the results were presented in Tukey style box and whisker plots.
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